287,314 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Nuveen LLC

Key Points

• Nuveen LLC has acquired a new stake in IDEAYA Biosciences, purchasing 287,314 shares valued at approximately $4.7 million, representing 0.33% of the company's stock.
• IDEAYA reported a quarterly loss of ($0.88) EPS, missing estimates by ($0.03), while its revenue of $6 million surpassed expectations.
• Analyst recommendations for IDEAYA are generally positive, with a consensus rating of "Moderate Buy" and an average price target of $47.10.

Nuveen LLC acquired a new stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 287,314 shares of the company's stock, valued at approximately $4,706,000. Nuveen LLC owned about 0.33% of IDEAYA Biosciences at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in IDYA. GF Fund Management CO. LTD. purchased a new position in IDEAYA Biosciences in the 4th quarter valued at about $47,000. CWM LLC grew its position in IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after acquiring an additional 1,814 shares in the last quarter. PNC Financial Services Group Inc. grew its position in IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after acquiring an additional 1,546 shares in the last quarter. Signaturefd LLC increased its stake in shares of IDEAYA Biosciences by 374.8% in the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after buying an additional 2,271 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in IDEAYA Biosciences by 46.4% in the first quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $109,000 after purchasing an additional 2,112 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

IDYA has been the subject of several analyst reports. Wells Fargo & Company started coverage on shares of IDEAYA Biosciences in a report on Thursday, June 26th. They set an "overweight" rating and a $44.00 price target for the company. The Goldman Sachs Group upgraded shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target on the stock in a research report on Thursday, July 10th. JPMorgan Chase & Co. boosted their price target on shares of IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an "overweight" rating in a research report on Monday, July 28th. TD Cowen assumed coverage on shares of IDEAYA Biosciences in a research report on Tuesday, July 22nd. They issued a "buy" rating on the stock. Finally, Royal Bank Of Canada upgraded shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and dropped their price target for the stock from $57.00 to $30.00 in a research report on Wednesday, July 9th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $47.10.

IDEAYA Biosciences Trading Down 1.5%

NASDAQ:IDYA traded down $0.38 on Friday, hitting $24.55. 632,810 shares of the company's stock traded hands, compared to its average volume of 877,057. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $40.25. The firm has a 50-day moving average price of $23.21 and a 200-day moving average price of $20.45.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same quarter in the previous year, the business posted ($0.68) earnings per share. IDEAYA Biosciences's quarterly revenue was up NaN% on a year-over-year basis. As a group, equities research analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.